CureVac RNA Printer

CureVac RNA Printer is a wholly owned CureVac subsidiary established in 2022 to advance The RNA Printer, an integrated and automated manufacturing platform for GMP-grade mRNA vaccines and therapeutics. Rather than operating as a conventional drug developer with a disclosed standalone clinical pipeline, the company is positioned as a platform and services business focused on end-to-end, small-scale, rapid mRNA production. The platform is intended to support decentralized and flexible manufacturing for applications including pandemic-response vaccines and personalized oncology therapies. CureVac has described the system as progressing through regulatory milestones, including a manufacturing license to support mRNA production for cancer vaccine development. Overall, the entity appears to function primarily as a strategic manufacturing and technology arm within the broader CureVac group.